1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
Ghasriani, H.
Belcourt, P.J.F.
Sauve, S.
Hodgson, D.J.
Gingras, G.
Brochu, D.
Gilbert, M.
Aubin, Y.
http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic
C8 H15 N O6
221.208
2-acetamido-2-deoxy-alpha-D-galactopyranose
N-acetyl-alpha-D-galactosamine; 2-acetamido-2-deoxy-alpha-D-galactose; 2-acetamido-2-deoxy-D-galactose; 2-acetamido-2-deoxy-galactose; N-ACETYL-2-DEOXY-2-AMINO-GALACTOSE
D-saccharide, alpha linking
C3 H7 N O2
89.093
y
ALANINE
L-peptide linking
C6 H15 N4 O2 1
175.209
y
ARGININE
L-peptide linking
C4 H8 N2 O3
132.118
y
ASPARAGINE
L-peptide linking
C4 H7 N O4
133.103
y
ASPARTIC ACID
L-peptide linking
C3 H7 N O2 S
121.158
y
CYSTEINE
L-peptide linking
C5 H10 N2 O3
146.144
y
GLUTAMINE
L-peptide linking
C5 H9 N O4
147.129
y
GLUTAMIC ACID
L-peptide linking
C2 H5 N O2
75.067
y
GLYCINE
peptide linking
C6 H10 N3 O2 1
156.162
y
HISTIDINE
L-peptide linking
C6 H13 N O2
131.173
y
ISOLEUCINE
L-peptide linking
C6 H13 N O2
131.173
y
LEUCINE
L-peptide linking
C6 H15 N2 O2 1
147.195
y
LYSINE
L-peptide linking
C5 H11 N O2 S
149.211
y
METHIONINE
L-peptide linking
C9 H11 N O2
165.189
y
PHENYLALANINE
L-peptide linking
C5 H9 N O2
115.130
y
PROLINE
L-peptide linking
C3 H7 N O3
105.093
y
SERINE
L-peptide linking
C4 H9 N O3
119.119
y
THREONINE
L-peptide linking
C11 H12 N2 O2
204.225
y
TRYPTOPHAN
L-peptide linking
C9 H11 N O3
181.189
y
TYROSINE
L-peptide linking
C5 H11 N O2
117.146
y
VALINE
L-peptide linking
US
J.Biol.Chem.
JBCHA3
0071
0021-9258
288
247
254
10.1074/jbc.M112.413252
23184955
A single N-acetylgalactosamine residue at threonine 106 modifies the dynamics and structure of interferon alpha2a around the glycosylation site.
2013
10.2210/pdb2lms/pdb
pdb_00002lms
19395.291
Interferon alpha-2
1
man
polymer
221.208
2-acetamido-2-deoxy-alpha-D-galactopyranose
1
man
non-polymer
IFN-alpha-2, Interferon alpha-A, LeIF A
no
no
MCDLPQTHSLGSRRTLMLLAQMRKISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDET
LLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQE
SLRSKE
MCDLPQTHSLGSRRTLMLLAQMRKISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDET
LLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQE
SLRSKE
A
polypeptide(L)
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
human
sample
IFNA2
9606
Homo sapiens
469008
Escherichia coli
BL21
DE3
pET-15b
atom_site
chem_comp
entity
pdbx_chem_comp_identifier
pdbx_entity_nonpoly
pdbx_nmr_spectrometer
struct_conn
struct_ref_seq_dif
struct_site
struct_site_gen
chem_comp
database_2
pdbx_database_status
repository
Initial release
Carbohydrate remediation
repository
Remediation
Database references
Atomic model
Data collection
Database references
Derived calculations
Structure summary
Database references
Other
Structure summary
1
0
2012-12-05
1
1
2013-05-01
2
0
2020-07-29
2
1
2023-06-14
_atom_site.auth_atom_id
_atom_site.label_atom_id
_chem_comp.name
_chem_comp.type
_entity.pdbx_description
_pdbx_entity_nonpoly.name
_pdbx_nmr_spectrometer.model
_struct_conn.pdbx_leaving_atom_flag
_struct_conn.pdbx_role
_struct_ref_seq_dif.details
_chem_comp.pdbx_synonyms
_database_2.pdbx_DOI
_database_2.pdbx_database_accession
_pdbx_database_status.status_code_nmr_data
DGalpNAca
N-acetyl-a-D-galactopyranosamine
a-D-GalpNAc
GalNAc
BMRB
Y
RCSB
2011-12-12
REL
REL
REL
REL
A2G
2-acetamido-2-deoxy-alpha-D-galactopyranose
structures with the least restraint violations
100
20
3D HNCO
3D HNCA
3D HNCACB
3D CBCA(CO)NH
3D HBHA(CO)NH
3D HCCH-TOCSY
3D 1H-15N NOESY
3D 1H-13C NOESY aliphatic
3D 1H-13C NOESY aromatic
3D C(CO)NH
2D (hb)CB(cgcd)HD
2D (hb)CB(cgcdce)HE
4D (C13)HSQC-NOESY-(N15)HSQC
4D (C13)HSQC-NOESY-(C13)HSQC
0.85
mM
[U-100% 13C; U-100% 15N]
0.53
mM
[U-100% 13C; U-100% 15N]
0.87
mM
[U-100% 13C; U-100% 15N]
25
3.5
ambient
298.15
K
torsion angle dynamics
1
fewest violations
0.85 mM [U-100% 13C; U-100% 15N] Interferon Alpha-2a (O-glycosylated), 90% H2O/10% D2O
90% H2O/10% D2O
0.87 mM [U-100% 13C; U-100% 15N] Interferon Alpha-2a (O-glycosylated), 100% D2O
100% D2O
Guntert, Mumenthaler and Wuthrich
structure solution
CYANA
2.1
Guntert, Mumenthaler and Wuthrich
refinement
CYANA
700
Bruker
AVANCE
Bruker Avance
600
Bruker
AVANCE III
Bruker Avance III
A2G
500
2
A2G
A2G
500
A
n
1
0
A
CYS
1
n
2
CYS
1
A
ASP
2
n
3
ASP
2
A
LEU
3
n
4
LEU
3
A
PRO
4
n
5
PRO
4
A
GLN
5
n
6
GLN
5
A
THR
6
n
7
THR
6
A
HIS
7
n
8
HIS
7
A
SER
8
n
9
SER
8
A
LEU
9
n
10
LEU
9
A
GLY
10
n
11
GLY
10
A
SER
11
n
12
SER
11
A
ARG
12
n
13
ARG
12
A
ARG
13
n
14
ARG
13
A
THR
14
n
15
THR
14
A
LEU
15
n
16
LEU
15
A
MET
16
n
17
MET
16
A
LEU
17
n
18
LEU
17
A
LEU
18
n
19
LEU
18
A
ALA
19
n
20
ALA
19
A
GLN
20
n
21
GLN
20
A
MET
21
n
22
MET
21
A
ARG
22
n
23
ARG
22
A
LYS
23
n
24
LYS
23
A
ILE
24
n
25
ILE
24
A
SER
25
n
26
SER
25
A
LEU
26
n
27
LEU
26
A
PHE
27
n
28
PHE
27
A
SER
28
n
29
SER
28
A
CYS
29
n
30
CYS
29
A
LEU
30
n
31
LEU
30
A
LYS
31
n
32
LYS
31
A
ASP
32
n
33
ASP
32
A
ARG
33
n
34
ARG
33
A
HIS
34
n
35
HIS
34
A
ASP
35
n
36
ASP
35
A
PHE
36
n
37
PHE
36
A
GLY
37
n
38
GLY
37
A
PHE
38
n
39
PHE
38
A
PRO
39
n
40
PRO
39
A
GLN
40
n
41
GLN
40
A
GLU
41
n
42
GLU
41
A
GLU
42
n
43
GLU
42
A
PHE
43
n
44
PHE
43
A
GLY
44
n
45
GLY
44
A
ASN
45
n
46
ASN
45
A
GLN
46
n
47
GLN
46
A
PHE
47
n
48
PHE
47
A
GLN
48
n
49
GLN
48
A
LYS
49
n
50
LYS
49
A
ALA
50
n
51
ALA
50
A
GLU
51
n
52
GLU
51
A
THR
52
n
53
THR
52
A
ILE
53
n
54
ILE
53
A
PRO
54
n
55
PRO
54
A
VAL
55
n
56
VAL
55
A
LEU
56
n
57
LEU
56
A
HIS
57
n
58
HIS
57
A
GLU
58
n
59
GLU
58
A
MET
59
n
60
MET
59
A
ILE
60
n
61
ILE
60
A
GLN
61
n
62
GLN
61
A
GLN
62
n
63
GLN
62
A
ILE
63
n
64
ILE
63
A
PHE
64
n
65
PHE
64
A
ASN
65
n
66
ASN
65
A
LEU
66
n
67
LEU
66
A
PHE
67
n
68
PHE
67
A
SER
68
n
69
SER
68
A
THR
69
n
70
THR
69
A
LYS
70
n
71
LYS
70
A
ASP
71
n
72
ASP
71
A
SER
72
n
73
SER
72
A
SER
73
n
74
SER
73
A
ALA
74
n
75
ALA
74
A
ALA
75
n
76
ALA
75
A
TRP
76
n
77
TRP
76
A
ASP
77
n
78
ASP
77
A
GLU
78
n
79
GLU
78
A
THR
79
n
80
THR
79
A
LEU
80
n
81
LEU
80
A
LEU
81
n
82
LEU
81
A
ASP
82
n
83
ASP
82
A
LYS
83
n
84
LYS
83
A
PHE
84
n
85
PHE
84
A
TYR
85
n
86
TYR
85
A
THR
86
n
87
THR
86
A
GLU
87
n
88
GLU
87
A
LEU
88
n
89
LEU
88
A
TYR
89
n
90
TYR
89
A
GLN
90
n
91
GLN
90
A
GLN
91
n
92
GLN
91
A
LEU
92
n
93
LEU
92
A
ASN
93
n
94
ASN
93
A
ASP
94
n
95
ASP
94
A
LEU
95
n
96
LEU
95
A
GLU
96
n
97
GLU
96
A
ALA
97
n
98
ALA
97
A
CYS
98
n
99
CYS
98
A
VAL
99
n
100
VAL
99
A
ILE
100
n
101
ILE
100
A
GLN
101
n
102
GLN
101
A
GLY
102
n
103
GLY
102
A
VAL
103
n
104
VAL
103
A
GLY
104
n
105
GLY
104
A
VAL
105
n
106
VAL
105
A
THR
106
n
107
THR
106
A
GLU
107
n
108
GLU
107
A
THR
108
n
109
THR
108
A
PRO
109
n
110
PRO
109
A
LEU
110
n
111
LEU
110
A
MET
111
n
112
MET
111
A
LYS
112
n
113
LYS
112
A
GLU
113
n
114
GLU
113
A
ASP
114
n
115
ASP
114
A
SER
115
n
116
SER
115
A
ILE
116
n
117
ILE
116
A
LEU
117
n
118
LEU
117
A
ALA
118
n
119
ALA
118
A
VAL
119
n
120
VAL
119
A
ARG
120
n
121
ARG
120
A
LYS
121
n
122
LYS
121
A
TYR
122
n
123
TYR
122
A
PHE
123
n
124
PHE
123
A
GLN
124
n
125
GLN
124
A
ARG
125
n
126
ARG
125
A
ILE
126
n
127
ILE
126
A
THR
127
n
128
THR
127
A
LEU
128
n
129
LEU
128
A
TYR
129
n
130
TYR
129
A
LEU
130
n
131
LEU
130
A
LYS
131
n
132
LYS
131
A
GLU
132
n
133
GLU
132
A
LYS
133
n
134
LYS
133
A
LYS
134
n
135
LYS
134
A
TYR
135
n
136
TYR
135
A
SER
136
n
137
SER
136
A
PRO
137
n
138
PRO
137
A
CYS
138
n
139
CYS
138
A
ALA
139
n
140
ALA
139
A
TRP
140
n
141
TRP
140
A
GLU
141
n
142
GLU
141
A
VAL
142
n
143
VAL
142
A
VAL
143
n
144
VAL
143
A
ARG
144
n
145
ARG
144
A
ALA
145
n
146
ALA
145
A
GLU
146
n
147
GLU
146
A
ILE
147
n
148
ILE
147
A
MET
148
n
149
MET
148
A
ARG
149
n
150
ARG
149
A
SER
150
n
151
SER
150
A
PHE
151
n
152
PHE
151
A
SER
152
n
153
SER
152
A
LEU
153
n
154
LEU
153
A
SER
154
n
155
SER
154
A
THR
155
n
156
THR
155
A
ASN
156
n
157
ASN
156
A
LEU
157
n
158
LEU
157
A
GLN
158
n
159
GLN
158
A
GLU
159
n
160
GLU
159
A
SER
160
n
161
SER
160
A
LEU
161
n
162
LEU
161
A
ARG
162
n
163
ARG
162
A
SER
163
n
164
SER
163
A
LYS
164
n
165
LYS
164
A
GLU
165
n
166
GLU
165
A
author_defined_assembly
1
monomeric
A
THR
106
GLYCOSYLATION SITE
A
THR
107
THR
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
1_555
x,y,z
identity operation
0.0000000000
0.0000000000
0.0000000000
1
A
MET
0
A
MET
1
1
Y
2
A
MET
0
A
MET
1
1
Y
3
A
MET
0
A
MET
1
1
Y
4
A
MET
0
A
MET
1
1
Y
5
A
MET
0
A
MET
1
1
Y
6
A
MET
0
A
MET
1
1
Y
7
A
MET
0
A
MET
1
1
Y
8
A
MET
0
A
MET
1
1
Y
9
A
MET
0
A
MET
1
1
Y
10
A
MET
0
A
MET
1
1
Y
11
A
MET
0
A
MET
1
1
Y
12
A
MET
0
A
MET
1
1
Y
13
A
MET
0
A
MET
1
1
Y
14
A
MET
0
A
MET
1
1
Y
15
A
MET
0
A
MET
1
1
Y
16
A
MET
0
A
MET
1
1
Y
17
A
MET
0
A
MET
1
1
Y
18
A
MET
0
A
MET
1
1
Y
19
A
MET
0
A
MET
1
1
Y
20
A
MET
0
A
MET
1
1
Y
1
A
PRO
4
-69.83
68.12
1
A
CYS
29
-155.93
88.97
1
A
ASP
32
-130.31
-31.51
1
A
ASP
35
178.85
166.24
1
A
PRO
39
-69.79
81.17
1
A
ASN
45
-155.83
73.05
1
A
PHE
84
-63.22
-74.62
1
A
SER
163
-52.05
103.60
2
A
LEU
3
-46.97
156.04
2
A
PRO
4
-69.74
65.92
2
A
CYS
29
-157.43
85.50
2
A
HIS
34
62.07
81.24
2
A
ASP
35
-132.08
-43.17
2
A
PRO
39
-69.79
81.30
2
A
PHE
84
-62.41
-72.61
3
A
LEU
3
-48.74
156.66
3
A
PRO
4
-69.80
64.05
3
A
CYS
29
-159.18
84.10
3
A
HIS
34
60.39
100.24
3
A
ASP
35
-151.88
-41.44
3
A
PRO
39
-69.79
83.72
3
A
ASN
45
-149.82
59.35
3
A
PHE
84
-62.93
-72.28
3
A
ASN
156
-100.20
63.63
3
A
LEU
161
-73.48
-74.98
4
A
LEU
3
-47.92
156.92
4
A
PRO
4
-69.81
68.57
4
A
CYS
29
-155.29
88.59
4
A
HIS
34
51.52
89.22
4
A
ASP
35
-139.26
-56.27
4
A
PRO
39
-69.80
81.85
4
A
PHE
84
-60.25
-72.05
4
A
SER
136
-49.72
168.41
5
A
LEU
3
-47.93
157.13
5
A
PRO
4
-69.76
76.06
5
A
CYS
29
-153.67
89.39
5
A
ASP
35
-166.91
-50.80
5
A
PRO
39
-69.72
75.29
5
A
ASN
45
-151.46
53.93
5
A
PHE
84
-62.75
-72.13
5
A
SER
160
-151.47
25.93
5
A
LEU
161
-92.36
-75.37
6
A
LEU
3
-47.15
158.73
6
A
PRO
4
-69.81
65.29
6
A
CYS
29
-152.35
88.56
6
A
HIS
34
58.89
95.06
6
A
ASP
35
-148.74
-50.65
6
A
PRO
39
-69.80
81.95
6
A
PHE
84
-59.47
-71.66
6
A
LYS
164
-98.58
39.16
7
A
LEU
3
-49.08
158.32
7
A
PRO
4
-69.80
64.70
7
A
CYS
29
-162.31
88.39
7
A
HIS
34
58.72
98.01
7
A
ASP
35
-159.34
-42.27
7
A
PRO
39
-69.81
77.34
7
A
GLN
46
-95.57
34.08
7
A
PHE
84
-58.21
-71.98
7
A
ASN
156
-103.16
58.81
7
A
LEU
161
-68.04
-74.93
8
A
LEU
3
-48.26
158.43
8
A
PRO
4
-69.79
69.69
8
A
CYS
29
-159.35
86.56
8
A
HIS
34
51.37
84.20
8
A
ASP
35
-138.39
-42.21
8
A
PRO
39
-69.77
91.38
8
A
ASN
45
-154.89
61.72
8
A
PHE
84
-58.77
-71.57
8
A
SER
136
-49.81
168.75
8
A
ASN
156
-90.16
59.89
8
A
LEU
161
-89.77
-74.90
9
A
LEU
3
-48.29
158.26
9
A
PRO
4
-69.83
70.01
9
A
CYS
29
-152.95
87.60
9
A
ASP
35
-170.01
-40.23
9
A
PHE
36
-52.08
-71.57
9
A
PRO
39
-69.75
86.79
9
A
GLN
46
-94.57
39.02
9
A
PHE
84
-63.67
-72.50
9
A
GLN
101
-59.56
175.28
9
A
SER
160
-178.87
86.27
10
A
LEU
3
-48.02
158.92
10
A
PRO
4
-69.78
65.37
10
A
CYS
29
-154.38
88.02
10
A
ASP
35
-159.01
-52.65
10
A
PRO
39
-69.71
80.92
10
A
PHE
84
-61.30
-72.00
10
A
GLU
159
-179.65
-173.89
11
A
ASP
2
-112.57
66.78
11
A
PRO
4
-69.76
62.90
11
A
CYS
29
-155.24
88.62
11
A
ASP
35
-162.38
-44.30
11
A
PRO
39
-69.71
81.91
11
A
ASN
45
-159.01
76.56
11
A
PHE
84
-61.88
-72.09
11
A
SER
160
-159.45
30.42
11
A
LEU
161
-89.46
-75.53
11
A
ARG
162
-97.99
-66.82
12
A
LEU
3
-47.89
159.43
12
A
PRO
4
-69.73
69.50
12
A
ASP
35
-157.07
-41.37
12
A
PRO
39
-69.85
78.96
12
A
PHE
84
-60.16
-72.06
12
A
SER
160
-149.20
24.69
13
A
LEU
3
-48.24
158.98
13
A
PRO
4
-69.72
74.20
13
A
CYS
29
-157.38
83.58
13
A
HIS
34
59.36
99.62
13
A
ASP
35
-151.54
-41.45
13
A
PRO
39
-69.80
85.37
13
A
ASN
45
-159.25
56.63
13
A
PHE
84
-60.10
-71.87
13
A
LEU
161
-68.83
-176.40
14
A
LEU
3
-48.80
156.85
14
A
PRO
4
-69.76
65.84
14
A
CYS
29
-151.53
87.48
14
A
ASP
35
-121.72
-58.36
14
A
PRO
39
-69.80
82.15
14
A
ASN
45
-155.79
42.08
14
A
PHE
84
-61.59
-72.11
15
A
LEU
3
-48.45
150.45
15
A
PRO
4
-69.78
85.65
15
A
CYS
29
-152.35
88.14
15
A
ASP
35
-159.30
-41.77
15
A
PRO
39
-69.81
88.85
15
A
ASN
45
-144.76
44.28
15
A
PHE
84
-59.07
-71.54
15
A
ASN
156
-104.24
56.46
15
A
LEU
161
-105.32
-71.36
16
A
PRO
4
-69.80
62.69
16
A
PHE
36
-92.37
40.80
16
A
PRO
39
-69.79
80.86
16
A
GLN
46
-91.69
40.04
16
A
PHE
84
-62.02
-71.14
16
A
SER
136
-49.91
168.34
16
A
SER
160
-61.98
93.80
16
A
LEU
161
-145.82
-67.78
17
A
LEU
3
-47.61
155.86
17
A
PRO
4
-69.72
67.99
17
A
CYS
29
-154.79
89.00
17
A
ASP
35
-146.78
-45.61
17
A
PRO
39
-69.81
78.18
17
A
ASN
45
-160.00
45.22
17
A
PHE
84
-61.56
-71.78
17
A
SER
136
-49.78
168.92
17
A
LEU
161
-71.74
-168.69
17
A
LYS
164
-72.43
-71.62
18
A
LEU
3
-47.28
160.73
18
A
PRO
4
-69.80
69.72
18
A
CYS
29
-158.01
88.26
18
A
HIS
34
59.09
100.73
18
A
ASP
35
-153.37
-41.28
18
A
PRO
39
-69.80
78.25
18
A
PHE
84
-58.83
-71.75
18
A
VAL
105
-175.84
136.64
18
A
LYS
164
-95.82
36.86
19
A
LEU
3
-49.54
158.74
19
A
PRO
4
-69.72
78.00
19
A
CYS
29
-151.82
87.54
19
A
ASP
35
-176.31
-35.83
19
A
PHE
36
-53.73
-72.25
19
A
PRO
39
-69.75
89.29
19
A
PHE
84
-59.99
-72.46
19
A
ASN
156
-89.57
48.60
19
A
LYS
164
-74.93
-72.20
20
A
LEU
3
-47.26
155.47
20
A
PRO
4
-69.72
70.77
20
A
CYS
29
-151.60
87.49
20
A
ASP
35
-160.83
-40.39
20
A
PRO
39
-69.78
84.96
20
A
ASN
45
-151.17
37.26
20
A
GLN
46
-93.60
39.16
20
A
PHE
84
-61.61
-71.91
20
A
ASN
156
-101.35
61.02
20
A
SER
160
-146.99
30.24
20
A
LEU
161
-89.34
-75.18
fewest violations, model 1
A single GalNAc residue on Threonine-106 modifies the dynamics and the structure of Interferon alpha-2a around the glycosylation site
1
N
N
2
N
N
A
LEU
9
A
LEU
10
HELX_P
A
ARG
22
A
ARG
23
1
1
14
A
SER
25
A
SER
26
HELX_P
A
CYS
29
A
CYS
30
5
2
5
A
PRO
39
A
PRO
40
HELX_P
A
GLY
44
A
GLY
45
1
3
6
A
GLU
51
A
GLU
52
HELX_P
A
SER
68
A
SER
69
1
4
18
A
THR
69
A
THR
70
HELX_P
A
TRP
76
A
TRP
77
1
5
8
A
ASP
77
A
ASP
78
HELX_P
A
GLN
101
A
GLN
102
1
6
25
A
THR
108
A
THR
109
HELX_P
A
LYS
133
A
LYS
134
1
7
26
A
CYS
138
A
CYS
139
HELX_P
A
ASN
156
A
ASN
157
1
8
19
disulf
2.141
A
CYS
1
A
SG
CYS
2
1_555
A
CYS
98
A
SG
CYS
99
1_555
disulf
1.946
A
CYS
29
A
SG
CYS
30
1_555
A
CYS
138
A
SG
CYS
139
1_555
covale
1.540
one
O-Glycosylation
A
THR
106
A
OG1
THR
107
1_555
A
A2G
500
B
C1
A2G
1_555
IMMUNE SYSTEM
CYTOKINE, GLYCOPROTEIN, O-GLYCOSYLATION, SIGNALING PROTEIN, TYPE I INTERFERONS, IMMUNE SYSTEM
IFNA2_HUMAN
UNP
1
24
P01563
CDLPQTHSLGSRRTLMLLAQMRKISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETL
LDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQES
LRSKE
24
188
2LMS
1
165
P01563
A
1
2
166
1
initiating methionine
MET
0
2LMS
A
P01563
UNP
1